The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) team is pleased to announce that it was recently awarded the Canadian Cancer Society Research Institute’s (CCSRI) Innovation to Impact Grant to support the further development of the successful findings of the PARITY pilot study based on the goals originally explored through the CCSRI Innovation Grant. This application round was highly competitive, with only 3 of 19 applications having been approved – a 16% success rate. The PARITY trial was funded to its full panel recommended amounts and no administrative decrements were applied. Funds committed to this competition have been made possible by the significant efforts of the Canadian Cancer Society volunteers and donors across the country, for which the PARITY team is tremendously grateful.
The PARITY network is a collaboration that brings together experts in clinical trials, biostatistics, orthopaedic surgery, oncology, pharmacy, and research coordination. This renowned group is proving that orthopaedic oncology can lead transformational research programs around the world. The PARITY trial is the first ever multi-center randomized controlled trial in orthopaedic oncology and its recent initiation is a groundbreaking advancement towards evidence-based practice in this field. We look forward to continuing the definitive phase of the trial with this CCSRI funding.